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/t is not what we know that is important, 
it is what we do not know. 
Charles F. Kettering 
A task without a vision is drudgery. 
A vision without a task is a dream. 
A task with a vision is victory. 
To Wesley, 
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Abstract- Photodynamic therapy is a promising treatment modality that involves the 
localization of a light-sensitive drug or photosensitizer in the target tissue prior to 
illumination with visible light. In the presence of molecular oxygen, cytotoxic agents are 
generated upon illumination and trigger a cascade of biochemical responses that may 
eradicate both malignant and non-malignant conditions. Phthalocyanine derivatives are 
second generation photosensitizers with enhanced photophysical, photochemical and 
photobiological properties as compared to the clinically accepted hematoporphyrin 
derivative Photofrin®. The current study aims at improving the targeting of these 
photosensitizers to cancerous tissues either through modifications on the phthalocyanine 
macrocycle or through protein carriers. AlPcS4 derivatives substituted with long aliphatic 
chains of varying lengths were photodynamically active in vitro against a lung 
adenocarcinoma cell line, A549 cells. Activity varied directly with the degree of 
lipophilicity: AlPcS4(Cl6) > AlPcS4(Cl2) > AlPcS4(C8) > AlPcS4(C4). In vivo studies 
using the EMT-6 murine model were promising, requiring 0.2 µmol kg- 1 and 400 J cm-2 
to completely ablate the tumor. LDL receptor expression is often upregulated in cancer 
cell membranes. Therefore, in order to enhance Pc targeting, LDL was loaded with 
AlPcS by two different approaches. The AIPcS4(Cl2) derivative was non-covalently 
inserted in the phospholipid bilayer of LDL particles. Conversely, AIPcS4 substituted 
with two caproic acid spacer chains were covalently attached to the LDL protein moiety. 
While the latter had only marginal success, the former proved to be photodynamically 
active both in vitro and in vivo. To further exploit cell surface receptors as potential 
targets in PDT, adeno-viral proteins were covalently labeled with AIPcS4. Adenoviruses 
penetrate the cell via receptor mediated endocytosis. The Ad penton base contains 5 
repeats of the peptidic RGD binding sequence. This motif binds with high affinity to 
several members of the integrin receptor family. Integrin receptors play a major role in 
tumorigenesis and metastases with altered expression being a factor. The class of 
integrin receptors with high affinity for the RGD sequence is expressed in high numbers 
on A549 cells. Cell uptake of the AIPcS4-adenovirus protein conjugates was enhanced 
over the parental Pc; however, photocytotoxicity results were unfavorable. In vivo 
studies using the same rodent model as that of the LDL study were encouraging. The 
AlPcS4-adenovirus protein conjugates caused complete tumor regression at a dose of 0.5 
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µmol kg·' and 400 J cm·2• The role of RGD on PDT induced cell death was also 
investigated. It was anticipated that soluble RGD would have a synergistic effect on PDT 
induced apoptosis yet the opposite was found. RGD enhanced cell survival following 
PDT in a dose dependent manner in both a receptor negative (EMT-6) and a receptor 
positive (A549) ceU line. This was an unexpected phenomenon and warrants further 
investigation. Once understood, the possibility of designing peptidic carriers for 
photosensitizers or adjunct therapies using the RGD peptide are within the realm of 
possibility. Nonetheless, specific targeting of AlPcS4 derivatives to cancer cells resulted 





Cancer is one of the leading causes of death and disease in the Western World. 
Over 1.2 million new cases of cancer were diagnosed in the United States in 1999 
(American Cancer Society) while approximately one third of the population of Western 
Europe can expect to be touched by the disease within their lifetime (Brown et al., 1999). 
Cancer is an unregulated proliferation of transformed cells displaying an altered 
phenotype, distorted differentiation and genetic instability. These cells usually spread to 
and infiltrate distant sites of the body, giving rise to metastases (Fingert et al, 1997). 
Traditional cancer treatment modalities such as surgery, chemotherapy and radiation 
therapy aim at locoregional or systemic control of the malignancy and involve a delicate 
balance between removing or destroying diseased tissue while sparing neighboring 
healthy cells. These conventional therapies produce serious side effects caused by the 
loss of normal cell function as a result of their relatively indiscriminate cytotoxic effects. 
Furthermore, despite operating at near optimal efficiencies, these treatment protocols 
often are not sufficiently effective, frequently leading to important recurrences. While 
therapeutic improvements are continually being made, there have been no substantial 
enhancements in survival for a number of major malignancies over the past decade 
(Brown et al., 1999). Consequently, the search for new and improved treatment protocols 
that exhibit more selectivity for diseased tissue and less morbidity remains unabated. 
Photodynamic therapy (PDT) is a promising new treatment modality that has 
recently been accepted in clinic as a curative and/or palliative therapy for cancer and also 
for non-malignant disorders. Photodynamic therapy entails a classic binary system which 
combines a light-activated drug (photosensitizer) with light of the appropriate wavelength 
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that is consistent with the absorption spectrum of the given photosensitizer. Illumination 
of the photosensitizer typically with visible light triggers a sequence of photophysical, 
photochemical and photobiological processes that cause irreversible photodamage to the 
target tissue. Neither the photosensitizer nor the light are harmful by themselves and 
only produce cytotoxic species when combined in the presence of rnolecular oxygen. 
Like all new cancer therapies, PDT prirnarily airns at destroying diseased tissue without 
causing inordinate injury to surrounding healthy cells. This targeting of diseased tissue is 
aided by a number of factors unique to PDT. The dual selectivity of PDT is produced by 
both a preferential uptake and/or prolonged retention of the photosensitizer by the 
diseased tissue along with the ability to confine activation of the photosensitizer to the 
target volume. This is accomplished by restricting the illumination to that specific 
volume, often using lasers and fiber optics. Hence, PDT allows for the selective 
destruction of tumors, providing the potential for minimal morbidity and large therapeutic 
indices. 
1.1 Historkal perspective 
The therapeutic benefits of light have been known since the ancient world with 
early Greek, Egyptian, Roman and Indian civilizations ail recognizing the healing powers 
of the sun. In India, as early as 1400 B.C., extracts of Psoralea corylifolia were given 
orally, followed by exposure to sunlight, in order to treat vitiligo (Daniell and Hill, 1991; 
Bonnert, 1999). Modern photodynamic therapy however can trace its origins to the 
beginning of the 20th century when a rnedical student, Oscar Raab, working under the 
direction of Dr. von Tappeiner in Munich, noticed the lethal effects oflight on Paramecia 
treated with acridine dyes (Raab, 1900). This phenomenon was more extensively studied 
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by von Tappeiner and Jodlbauer who coined the term "photodynamic action" (von 
Tappeiner and Jodlbauer, 1907). It was noted that other compounds such as eosin were 
able to induce rapid cell kill in the presence of light. It was established that dissolved 
molecular oxygen is needed for the reaction to occur. The first attempt at using PDT as a 
cancer treatment dates to 1903 where topically applied eosin was used in conjunction 
with sunlight to treat skin cancer (von Tappeiner and Jesionek, 1903). The relative 
specificity of POT was clearly demonstrated by Lipson in 1961 when the use of 
hematoporphyrin derivative (HpD) for the fluorescent detection of tumor tissue was 
reported (Lipson et al., 1961 ). In 1975, Dougherty first reported the eradication of 
transplanted animal tumors with HpD and red light without excessive damage to 
surrounding skin (Dougherty et al., 1975). This was soon followed by the first systemic 
clinical trials in humans and since then the field of PDT has rapidly expanded (Dougherty 
et al., 1978). Due to the clinical acceptance of Photofrin®, verteporfin and the prodrug 5-
aminolaevulinic acid (ALA), PDT has evolved into a useful treatment modality. 
1.2 Mechanisms of photosensitization 
Upon illumination, the photosensitizer is excited from its electronic ground state 
(So) to its first excited state (S1). This excited singlet state has a lifetime in the 
nanosecond range (Phillips, 1997), which is far too short for effective interaction with 
surrounding biological molecules. The S1 state can dissipate its excitation energy via 
radiative fluorescence or non-radiative internai conversion (IC). The most important of 
these processes in terms of PDT, however, is intersystem crossing (ISC) to the first 
excited triple state (Ti) with the corresponding change in electron spin. The lifetime of 
the T1 state is typically in the µs to ms range since the return T1 S0 is spin-forbidden 
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(Ochsner, 1997). The large increase in lifetime allows for the excited photosensitizer to 
internet with its environment and it is generally accepted that the triplet state is 
responsible for the generation of the cytotoxic species produced during POT in the 
majority of cases (Sharman et al., 2000). 
This excited triplet state can internet in one of two ways, defined as Type I and 
Type II (Figure 1 ). The T 1 state of the excited photosensitizer can be quenched via a 
hydrogen atom extraction or an electron transfer reaction with neighboring substrates. 
These reactions termed a Type I mechanism, lead to the formation of radicals and radical 
ions. These radical species react efficiently with molecular oxygen, leading to important 
oxidative damage and the production of reactive oxygen species such as superoxide 
anion, hydrogen peroxide and the hydroxyl radical. The following radical chain reactions 
cause important biological lesions. On the other hand, the T1 state can transfer its energy 
to molecular oxygen via a triplet-triplet annihilation reaction, generating singlet oxygen 
(Sharman et al., 2000). This Type II reaction mechanism has been shown to be 
predominant during POT. Singlet oxygen, the most important cytotoxic agent generated 
during POT, is highly reactive due to its zwitterionic character and can readily react with 
a number of biologically important substrates including amino acids, phospholipids, and 
nucleic acids (Singh, 1982). This leads to disruption of cellular and mitochondrial 
membranes, increased cellular permeability, the loss of vital protein and enzyme fonction 
and irreparable ONA damage, all of which can be lethal to the cell. It is generally 
accepted that the Type II mechanism prevails during POT and that singlet oxygen is the 
most important cytotoxic species produced (Sharman et al., 2000; Weishaupt et al., 1976; 
Valenzeno, 1987; Fuchs and Thiele, 1998). The range of singlet oxygen in cellular 
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medium is limited to approximately 45 nm (Moan and Boye, 1981 and Moan, 1990). 
With the diameter of human cells ranging from 104 to 105 nm, the site of primary 
generation of singlet oxygen consequently determines which subcellular target is 
attacked, either initiating an apoptotic or necrotic response. Appendix I outlines the 
importance of singlet oxygen in photodynamic therapy. However, while it is known that 
Type II processes predominate during PDT, Type I mechanisms become important at low 
oxygen concentrations and in more polar environments (Ochsner, 1997; Sharman et al., 
2000). These Type I mechanisms are no doubt involved in most photodynamic processes 
to a certain degree. Irrespective of the initial reaction, both Type I and Type II 
mechanisms lead to similar oxidative damage and comparable free radical chain 
reactions. The two processes, Type I and Type II are outlined in figure 1. 
Oxygemted Oxygemted 
Prodœts Sem Prodœts 
1 1 
Typel îYpeII 
Radicals or Sem* 10:2 
Radical iorn Stbstrate or 
Solveri 
Sernox+Oi-
Figure 1. Diagramatic presentation of Type I and Type II photosensitized oxidation 
reactions (Adapted from C. S. Foote, 1991) 
1.3 First generation photosensitizer: Hematoporphyrin derivative 
The first photosensitizers accepted for clinical use by governmental regulatory 
agencies are the first generation hematoporphyrin derivatives such as Photofrin®. 
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Photofrin®, an enriched sample of the more active dimeric and oligomeric components, 
has been accepted in several countries for the treatment of early- and late-stage lung 
cancer, superficial and advanced oesophageal cancer, bladder cancer, superficial and 
early-stage gastric cancer, early stage cervical cancer and cervical dysplasia. In addition, 
Photofrin® is being investigated as a possible therapy for a number of other malignant 
and non-malignant conditions. Other hematoporphyrin derivatives are also being used, 
with Photoheme accepted for clinical use in Russia for easily accessible cancers including 
skin, breast, oropharyngeal, lung, larynx and gastrointestinal cancers along with psoriasis 
and recurrent blindness (Sharman et al., 1999; Sobolev and Stranadko, 1997; Stranadko 
et al., 1996; Sokolov et al., 1994). 
Despite the clinical success achieved usmg Photofrin®, this first generation 
photosensitizer has several important drawbacks. It is a complex chemical mixture 
produced by the reaction of hematoporphyrin with 5% sulfuric acid in acetic acid 
followed by treatment with aqueous base and neutralization (Bonnett, 1995). The 
resulting dimers and oligomers, linked primarily with ester and ether bonds, may vary 
with different preparations and storage times and make structure-activity relationships 
impossible to determine (Brown and Truscott, 1993). It absorbs very weakly at the 
therapeutic wavelength of 630 nm, where tissue penetration of light is minimal, limiting 
treatment to tumor depths of no more than 5 mm (Wohrle et al., 1998). While suitable for 
more superficial lesions presently being treated, absorption at longer wavelengths is 
necessary to treat more deep-seated or larger tumors. In addition, hematoporphyrin 
derivatives have proven to be ineffective for such cancers as pigmented melanoma due to 
overlapping absorption spectra of the photosensitizer and melanin in the malignant tissue 
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(Peeva et al., 1999). Most importantly, hematoporphyrin derivatives exhibit an extended 
retention in cutaneous tissue for up to 10 weeks post-injection (Phillips, 1997). This 
results in a prolonged skin photosensitivity, an obvious disadvantage especially for 
patients with late stage malignancies. Nonetheless, the prolonged skin sensitivity 
induced by PDT with Photofrin ® is only a mild inconvenience as compared to the severe 
adverse effects of standard chemotherapeutic regimens. While these disadvantages have 
not prevented Photofrin® from becoming a useful drug against cancer and other 
conditions, the search for new second generation photosensitizers with improved 
physical, chemical and spectral properties remains an important goal (Sharman et al., 
1999; Ali and van Lier, 1999). 
Ideal photosensitizers for PDT must meet certain criteria, (Bonnett, 1999; 
Bonnett, 1995; Wôhrle et al., 1998; van Lier, 1988; MacRoberts et al., 1989) namely: 
0 It should be chemically pure and maintain a constant composition throughout 
treatment, undergoing minimal photobleaching. 
0 It should have minimal dark toxicity. 
@ The photosensitizer should be preferentially retained by the target tissue, whether 
malignant tumour cells or viral components, so as to induce only marginal toxicity to 
surrounding healthy biological matter. In addition, the excess dye should be rapidly 
excreted from the body exhibiting low systernic toxicity. 
0 The dye should have high photochemical reactivity with a high quantum yield of 
long-lived triplet-states energetic enough to produce singlet oxygen. 
• The sensitizer should have a large absorption coefficient at a long wavelength ( 600-
800 nm) where there is optimal tissue penetration by light with a low degree of 
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attenuation by hemoglobin. Furthermore, cheaper diode lasers can be used in this 
range, thus increasing the potential utility of PDT in a clinical setting. 
While no photosensitizer can be expected to fulfill ail of these parameters, 
numerous second generation photosensitizers have been investigated that can overcome 
the shortcomings of hematoporphyrin derivatives and take advantage of their more highly 
suited properties in order to treat a number of conditions. For instance, the use of 5-
aminolaevulinic acid (ALA)-induced endogenous photosensitizers has gained clinical 
acceptance for the treatment of actinie keratoses of the face and scalp. In the meanwhile 
verteporfin (benzoporphyrin derivative monoacid ring A) has received market approval in 
several countries including Switzerland, the United States and Canada, under the trade 
name Visudyne® as a therapy for wet age-related macular degeneration (AMD) a leading 
cause of blindness in people over the age of 50. Overall, the photosensitizer used to treat 
a given condition will greatly depend on the characteristics of the compound and the 
condition to be treated, with a wide range of different photosensitizers being used in 
clinic, each for its own particular use. Appendix II outlines the applications of several 
photosensitizers in pre-clinical and clinical trials. 
1.4 Second generation photosensitizers: Phthalocyanines 
Among the more promising second generation photosensitizers are 
phthalocyanines. The term phthalocyanine finds its origin in the Greek word "naptha" 
which means rock oil and "cyanine" which means dark blue. It was first used to describe 
this class of macrocyclic compounds by Sir Reginald Linstead in 1933 during his 
pioneering work on the subject (Linstead, 1934 ). In addition to the immediate 
applications as dyes and colorants, it was realized that such compounds would be of great 
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academic interest. As such, starting in 1929, Linstead and his group began their work on 
phthalocyanines which lead to the determination of their structure in the early l 930's 
(Linstead and Lowe, 1934; Dent et al., 1934; Linstead and Robertson, 1936). The 
synthesis of Pcs and their relationship to porphyrins, along with further examination into 
the intricate structure of Pcs, their planar nature, their complexes with metal ions and 
their stability were subsequently studied (Byrne et al., 1934; Linstead and Lowe, 1934; 
Dent and Linstead, 1934; Dent, 1938; Barrett et al., 1936; Barrett et al., 1938). The 
structure of phthalocyanines was later confirmed by Roberston via x-ray crystallography 
in a series of classic papers (Robertson, 1935; Robertson, 1936; Robertson and Woodard, 
1937; Roberston and Woodard, 1940). In the seventy years to follow this initial work, a 
plethora of information emerged concerning diverse synthetic routes, Pc photochemical 
and photophysical properties and potential applications. 
Of the utmost importance is their potential role in photodynamic therapy. These 
azaporphyrin derivatives have stronger absorbances at longer wavelengths than do 
porphyrins. Pcs have favorable photophysical and chemical properties. In addition, these 
properties can be altered through the addition of substituents to the periphery of the 
macrocycle or axial ligands to the chelated central metal ion. This makes them 
interesting photosensitizing agents. 
Phthalocyanine derivatives have attractive photophysical and photochemical 
properties as compared to hematoporphyrin derivatives. Monomeric Pcs have a 
characteristic absorption spectra with a strong Soret absorption peak at approximately 
350 nm, a weak maximum around 600 nm and a narrow, very strong, absoption peak in 
the far red region of the visible spectra (Pc Àmax;;:; 680 nm; HpD Àmax;;:; 630 nm) where 
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tissue penetration by visible light is supenor. In addition to the red-shift of 
phthalocyanine Q band absoption maxima, Pcs have an improved capacity to absorb 
light, by two orders of magnitude over that of the highest Q band absorption ofHpDs (Pc 
molar extinction coefficient (E) in the 105 M-lcm-1 range; HpD E M-lcm-1) (van 
Lier et al., 1988; van Lier and Spikes, 1989). These qualities therefore lead to enhanced 
photophysical and photochemical properties. 
The nature of the central metal ion influences the Pc photophysical properties 
(triplet quantum yield and lifetime). Complexation of Pcs with open shell or 
paramagnetic metal ions such as cu2+, Co2+, Fe2+, Nï2+, vo2+, Cr3+ and Pd2+ give 
dyes with shortened triplet lifetimes (nanosecond range) due to increased intersystem 
crossing back to the ground state, which renders the dye photoinactive (Chan et al., 
1987). Pcs containing closed d shell or dimagnetic metal ions, such as zn2+, At3+ and 
Ga3+, are dyes producing high triplet yields C<l>T > 0.4) with long lifetimes (tT > 200 µs) 
(Darwent, 1982). These triplet M-Pcs vary in energy from 110-126 kJ/mol which is 
ample energy to generate singlet oxygen (94.5 kJ/mol) with high quantum yields of 
approximately 0.3-0.5 (Wagner et al., 1987). Singlet oxygen yields are affected by ring 
substituents and axial ligands. Phthalocyanines tend to aggregate or dimerize which in 
tum determines the MPcSn activity (Wagner et al., 1987). Aggregation is easily detected 
spectroscopically as absorption occurs at shorter wavelengths in the Soret region and 
there is a 30-50 nm blue-shift of the Q band absorption peak which appears more broad 
and less intense. Disaggregation to form monomeric dyes can be accomplished by adding 
detergents, serum or plasma proteins or organic solvents (van Lier and Spikes, 1989; Ben 
Hur et al., 1987). 
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1.4.1 Phthalocyanine induced apoptosis or necrosis 
Phthalocyanines are very potent photosensitizers for use in PDT. Since first 
reported, several differently substituted Pc molecules have been synthesized and their 
PDT potential evaluated. Preliminary PDT results were promising using Pc derivatives, 
thus prompting more in depth studies regarding mode of cell death. 
Apoptosis is a notable mode of cell death in response to PDT usmg 
phthalocyanines (Oleinick, 1998). A promising phthalocyanine receiving a great deal of 
attention is the silicon Pc, denoted as Pc4, bearing a long chain amino axial ligand 
(HOSiPcOSi(CH3)2(CH2)3N(CH3) 2). This silicon phthalocyanine has shown promising 
results both in vitro and in vivo. Axial ligated Pcs have an important advantage over Pcs 
substituted on the periphery. Not only does the axial ligand impart greater solubility and 
prevent aggregation, these compounds do not have isomers, thus simplifying the 
preparation of pure samples. 
Pc4 has been shown to initiate an apoptotic response m several cell lines 
including L5 l 78Y-R cells. DNA fragmentation, a haUmark of apoptosis, was observed 
(He et al., 1997). This same research team demonstrated the importance of cell 
membrane damage with respect to apoptosis induction. Photodamaging the cell 
membrane initiates a cascade of events such as phospholipase C activation, release of 
secondary messengers and an increase in intracellular calcium concentration, all leading 
to cell suicide (Agarwal et al., 1993). Furthermore, an increase in intracellular calcium 
concentration also leads to the formation of nitric oxide (NO), an important bioactive 
signaling molecule. It has been demonstrated that NO is involved in PDT-mediated 
apoptosis (Gupta et al., l 998). In addition to NO, other well documented apoptotic 
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pathways are initiated by Pc4-PDT. Cytochrome c is released into the cytosol and 
subsequent activation of proteases, (Vames et al., 1999) now known as caspases, 
resulting in the cleavage of various proteins including poly(ADP-ribose)polymerase have 
been documented (He et al., 1998). Cell cycle arrest in the GO/G 1 phase of the cell cycle 
as a result of p2 l induction has been observed following Pc4 therapy (Agarwal et 
al., 1993). In addition, the participation of retinoblastoma protein has been studied 
following phototherapy (Ahmad et al., 1998). Several other apoptotic pathways and 
proteins involved in PDT mediated apoptosis are under investigation. 
Furthermore, enhanced apoptotic responses to photodynamic therapy with AlPc 
was observed after bcl-2 transfection (Choi Kim et al., 1999). Bcl-2 is a known inhibitor 
of apoptosis via antagonizing the release of mitochrondrial cytochrome c. In this case, 
using immortalized MCFlOA cells, overexpression of bcl-2 and bax was revealed and 
PDT caused selective destruction of bcl-2, leaving bax unaffected. As such, the greater 
apoptotic response towards PDT in this case is probably attributed to the higher bax:bcl-2 
ratio after photodamage. On the other hand, CHO-KI cells transfected with Bcl-2 
exhibited a partial resistance to PDT-induced cell death, either via apoptosis or non-
apoptotic mechanisms (He et al., 1996). 
Subsequently, it was demonstrated that the mode of cell death is not only 
dependant on cell type (i.e. fibroblasts do not die via organized DNA fragmentation (He 
et al., 1997)) but also on the photosensitizer, its intracellular localization and the drug and 
energy dose administered. In addition, it has recently been shown that the mode of cell 
death also varies with cell density due to the bystander effect (Dahle et al., 1999). Using 
AlPc and lower PDT doses resulted in the induction of apoptosis as opposed to necrosis. 
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Organelles such as the mitochondria and lysosymes were mainly affected. At higher 
PDT doses, cells underwent severe membrane damage resulting in necrosis (Luo and 
Kessel, l 997). Interestingly, Dellinger reported a mixed response when using Photofrin® 
and CV-1 cells (Dellinger, 1996). At higher irradiation doses, the cells lysed instead of 
exhibiting fragmentation associated with apoptosis. However, morphological changes 
typical of apoptosis were observed initially, such as plasma membrane blebbing, 
condensation of the cytoplasm and nuclear fragmentation. These cells appear to enter an 
apoptosis-like death, yet this pathway is stopped by plasma membrane lysis and 
ultimately, the cells undergo necrosis. ln vivo studies using the murine MS-2 
fibrosarcoma tumor model demonstrated random necrosis of tumor cells post ZnPc-PDT. 
Interestingly, apoptotic pathways were also detected, suggesting different localization of 
photosensitizers within the cell upon illumination (Jori and Fabris, 1998). 
Photodynamic therapy using phthalocyanines is known to induce a number of 
responses that ultimately lead to apoptosis. For instance, PDT using Pc4 induces an 
oxidative stress associated with increased ceramide generation (Separovic et al., 1997), 
which has been associated with apoptosis in several malignant and non-malignant cell 
lines. The increased production of ceramide is due to the stress-induced activation of 
sphingolyelinase (SMase ). It has been shown that normal human lymphoblasts 
accumulate ceramide and undergo apoptosis following Pc4-PDT. In contrast, Niemann-
Pick disease lymphoblasts, which are deficient in acid sphingomyelinase, fail to respond 
to Pc4-PDT via ceramide accumulation and apoptosis (Separovic et al., 1999). However, 
addition of exogenous bacterial Smase during Pc4-PDT induced a significant apoptotic 
response. This lead to the hypothesis that SMase may be an important proapoptotic 
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factor determining responsiveness of cells to Pc4-POT. Previous work showed that Pc4-
POT was able to induce apoptosis in numerous cell lines. Three cell lines were studied in 
vitro revealing the accumulation of ceramide post POT and induction of apoptosis. 
Interestingly, there were increased levels of ceramide in RIF-1 cells post POT with no 
evidence of apoptosis. Ceramide clearly is associated with POT-mediated cell death 
either by inducing apoptosis or necrosis (Separovic et al., 1998). 
1.4.2 Phthalocyanine delivery systems 
Targeting of photosensitizers is imperative, as singlet oxygen is extremely 
reactive thus limiting POT action to the site of singlet oxygen generation. As previously 
stated, its lifetime in biological systems has been estimated to be 200 ns with a diffusion 
range of 45 nm (Ochsner, 1997). Mammalian cells are 104 to 105 nm in diameter thus the 
importance of PS distribution within the target tissue is evident. Hydrophobie sensitizers 
have been shown to be biologically beneficial as compared to hydrophilic compounds. 
The former exhibits greater photocytotoxicity and tumor eradication, most probably 
because these hydrophobie dyes localize in more photosensitive cellular compartments. 
However in aqueous solutions, photosensitizers, either non-substituted or substituted with 
hydrophilic groups, tend to aggregate and dimerize which affects their cell penetrating 
properties and results in a loss of photochemical activity. Increased photodynamic action 
has been attributed to increased monomerization of the photosensitizer. 
Lipophilic photosensitizers require biologically compatible delivery systems. 
Nanoparticles have received attention as potential delivery vehicles for drug targeting. A 
hexadecafluoro zinc phthalocyanine was formulated in polyethylene-glycol-coated 
poly(lactic acid) nanoparticles and evaluated for POT e:fficiency. Using the EMT-6 
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tumor model, improved tumor response was observed using the nanoparticle formulation 
as compared to the same dye solubilized in Cremophor EL (Allémann et al., 1996). 
Nanoparticle formulation allows for increased serum levels of the dye as compared to 
Cremophor EL (CRM) formulation. Increased blood levels and enhanced tumor uptake 
lead to higher tumor-to-organ concentration ratios enhancing the overall dye efficacy 
(Allémann et al., 1995). Likewise pH-responsive, polymeric micelles consisting of 
random co-polymers of N-isopropylacrylamide, methacrylic acid and octadecyl acrylate 
have been loaded with water-insoluble AlPc and shown to exhibit higher phototoxicity 
against EMT-6 cells in vitro than the control CRM preparation (Taillerfer et al., 2000). 
ln addition to emulsifiers such as Cremophor EL, Solutol HS or lipid-based 
vehicles such as liposomes, a amount of research has focused on proteinic 
carriers for improved targeting of malignant cells. Serum lipoproteins can incorporate 
hydrophobie sensitizers into their lipid portion. Frequently, neoplastic cells have 
increased LDL receptors on the cell surface as increased proliferation requires cholesterol 
for membrane synthesis (Vitols, 1991). Subsequently, LDL are known to deliver 
photosensitizers to neoplastic cells through a receptor intemalization mechanism 
(Hamblin and Newman, 1994; Mazière et al., 1991; Allison et al., 1994). Jori and 
associates have do ne extensive studies using ZnPc incorporated into liposomes of varying 
composition. As will be discussed in greater detail later, Jori et al. have investigated the 
rote of serum lipoproteins and found them to be effective delivery vehicles for 
phthalocyanines (Polo et al., 1995; Reddi, 1997; Reddi et al., 1990; Valduga et al., 1999). 
Recently, a series of publications has reported the use of a modified aluminum 
tetrasulfophthalocyanine covalently coupled to various proteins via one or two caproic 
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acid spacer chains. Brasseur et. al. targeted the scavenger receptor of macrophages using 
a maleylated bovine serum albumin covalently labeled with AlPcS4. Relative 
photocytotoxicities were reported using a receptor positive and a receptor negative cell 
line where their lethal effects correlated with receptor affinity for the BSA-Pc conjugate 
(Brasseur et al., 1999). 
Using the same phthalocyanine derivative, it was found that covalently labeling a 
monoclonal antibody for the CD3+ antigen in a similar manner did not hinder receptor 
recognition. There was increased uptake of the antibody-Pc conjugate in a receptor 
positive cell line as compared to the free phthalocyanine and antibody-Pc uptake was less 
in a cell line void of receptors (Ménard, 1998). However, the Pc-antibody conjugates 
were photoinactive, most likely due to inefficient subcellular targeting. Similarly, AlPcS4 
was covalently coupled to monoclonal antibodies directed against carcinoembryonic 
antigen (CEA) (Carcenac et al., 1999). In vivo studies using nude mice bearing human 
colon carcinoma xenografts (T380) demonstrated increased uptake of the antibody-Pc 
conjugate as compared to the free Pc. In vitro results were encouraging using this 
antibody complex. 
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1.5 Research objectives 
Over the past 20 years, several photosensitizers have been synthesized and tested 
both in vitro and in vivo with varying results. Initially, this approach to POT was 
sufficient. However, more elaborate research is now underway to improve efficiency by 
targeting the photosensitizer (PS) to various tissue types. A number of second generation 
photosensitizers such as phthalocyanines are effective drugs for POT. However, to 
improve tumor uptake and preferential tumor-to-normal tissue ratios, third generation 
photosensitizers are being designed where the chromophore is tagged with a targeting 
system in order to improve these characteristics. 
The current research is sub-divided into four categories as represented by four 
research papers that have been published or submitted for publication as part of the 
present study. Chapter 2 presents results of a study employing a series of AlPc 
derivatives substituted with aliphatic chains of varying lengths on the Pc macrocycle 
imparting different lipophilicity. Amphiphilicity plays a major role in determining the 
usefulness of a Pc for POT. The first study investigates the POT potential of a series of 
amphiphilic AlPc derivatives as a function of lipophilicity. This study tests the 
hypothesis that amphiphilic phthalocyanines have improved POT potential. 
Subsequently, the role of low-density lipoproteins (LOL) as vehicles for AlPcS 
delivery to target tumor cells was evaluated and reported in chapter 3. Parallel studies 
using both non-covalently labeled and covalently labeled LOL to target human 
adenocarcinoma lung cancer cells (A549) were carried out. The amphiphilic AlPcS4 
molecule bearing a twelve-carbon alkyl side chain on the Pc macrocycle was 
noncovalently inserted in the LOL phospholipid layers. AlPcS4 was covalently coupled to 
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the apolipoprotein moiety via two sulfonamide five-carbon spacer chains. The two fold 
question addressed was whether or not LDL molecules are suitable vehicles for Pc 
delivery to the target tissue and whether Pc attachment to the protein or the lipid portion 
of the LDL affects PDT. 
Using the same principle, adenoviral proteins were employed to target lung cancer 
cells rich in the appropriate class of integrin receptors. Adenoviruses have been receiving 
a great deal of attention as gene therapy vectors. These viral particles gain entrance into 
the cells via receptor mediated endocytosis. Two receptors are required, the first for 
attachment and the other mediating intemalization. lntemalization of the virus particle is 
via integrin receptors able to bind with high affinity to the RGD binding motif found in 
the penton base protein of adenovirus. Chapter 4 outlines studies using the adenovirus 
capsid proteins covalently labeled with AlPcS4 derivatives. Is Pc delivery to cells 
improved and is PDT more efficient as a result of this? 
Tumor targeting using protein vehicles may have serious limitations invoking 
adverse immune responses. The search for small peptidic vectors was the rational behind 
the fourth objective of this thesis as described in chapter 5. The RGD peptide sequence is 
currently being investigated as a targeting vehicle for conventional chemotherapeutics. 
The present study evaluated the effects of RGD on cell survival following AlPcS2adj 
photodynamic treatment of both a receptor negative and a receptor positive cell line. 
Does RGD enhance Pc-PDT? 
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Chapter 2. 
Photodynamic properties of amphiphilic derivatives of aluminum 
tetrasulfophthalocyanine 
Cynthia M. Allen, Réjean Langlois, Wesley M. Sharman, Carole La Madeleine and 
Johan E. van Lier (2002) Photochem. Photobiol. 76, 208-216. 
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Second generation photosensitizers have several advantages over 
hematoporphyrin derivatives. However even the most potent chemotherapeutic agents 
are of no use if they don't target the desired tissue and can have deleterious effects. This 
alone outlines the importance of drug targeting. 
6.1 Amphiphilic phthalocyanines 
Substituents on the phthalocyanine framework have included aliphatic chains and 
higher order aromatics to improve both the solubility and potential usefulness of the Pc. 
The current study uses AlPcS4 substituted with aliphatic chains of increasing length. In 
general, amphiphilic molecules have been found to be more photodynamically active. 
The hydrophobie chain portion can slip into the cell membrane and anchor the Pc while 
their charged sulfonate groups interact with the aqueous layer outside the cell. Following 
48 hours incubation, the highest cellular concentration was observed with the more 
lipophilic AlPcS4(Cl6) derivative followed by the Cl2 < C8 < C4. The more hydrophilic 
compounds accumulated to a less extent. The AlPcS2adj, having a similar retention time 
on the HPLC column as the AlPcS4(Cl2), also had comparable A549 cell uptake 
properties. It is important to stipulate cell type as different cell types may exhibit 
different membrane permeation of the different Pc molecules. In addition, decreasing 
aggregation of the phthalocyanine enhances cell uptake of the sensitizer. In the present 
study the AlPcS4(Cl6) was initially solubilized in methanol then further diluted in PBS. 
The methanol was evaporated off leaving only trace arnounts. Studies where the 
AlPcS4(Cl6) derivative was dissolved directly in PBS resulted in different uptake by the 
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cells of the photosensitizer and the phototoxicity of the sensitizer was altered. This is 
most likely due to increased sensitizer aggregation. 
To circumvent such problems as aggregation but to retain the amphiphilic nature 
of the sensitizer, a series of silicon phthalocyanines with charge axial ligands was 
synthesized and tested on the EMT-6 cell line (Murphy et al., 2001). Axial ligated Pcs 
have an important advantage over Pcs substituted on the periphery. Not only does the 
axial ligand impart greater solubility and prevent aggregation these compounds do not 
have isomers, thus simplifying the preparation of pure samples. The SiPc in this study, 
with the longest axial ligand thus the more amphiphilic, was most phototoxic. This is 
comparable to the present study where the AlPcS4(C16) molecule was most photoactive. 
This increased length of the axial substituent presumably helps the dye to better partition 
into the membrane. A promising amphiphilic phthalocyanine receiving a great deal of 
attention is the silicon Pc, denoted as Pc4, bearing a long chain amino axial ligand 
(HOSiPcOSi(CH3)i(CH2)JN(CH3)i). Clinical trials are scheduled to begin in 2001 
(persona! communication). 
6.2 Protein carriers 
Site-specific drug delivery is an integrated part of the intellectual and 
experimental design of a therapeutic system. Enhanced delivery systems can access 
previously inaccessible cellular compartments thus reducing the amount of drug 
administered and protecting the body from unwanted accumulation and toxicity. The dye 
must be exclusively delivered to the pharmacological site of action at an appropriate dose 
to effectively combat the disease and improve the therapeutic index. As the 
pathophysiology of various diseases becomes known, researchers can exploit cellular 
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systems to increase dye uptake. Receptor-mediated endocytosis allows for the uptake 
and intracellular processing of macromolecules that bind to the cell surface receptors. 
Endocytosis of the plasma membrane is a continuous activity in many cell types 
occurring at a constant rate regardless of extemal stimuli. In this way, cell surface 
receptors are regularly re-distributed to the plasma membrane. Receptor intemalization 
can also be stimulated by ligand binding. It has been estimated that 80% of the epidermal 
growth factor (EGF) receptors intemalize within a half time of 2.5 minutes upon binding 
saturation (Hopkins, 1986). In view of this, drug trafficking across the cell plasma 
membrane is feasible. Additionally, protein carriers specifically targeting a cellular 
population will decrease liver entrapment of the photosensitizers as the drug package is 
strictly addressed. Several protein/receptor systems have been explored for the purpose 
of drug delivery. 
We report that the presence of 4 µg/mL of LDL slightly enhances the 
phototoxicity of the AlPcS4 derivatives substituted with long chains. Naturally, the next 
phase in this study was to incorporate these lipophilic sensitizers with LDL prior to 
administration. This was accomplished either via covalent or non-covalent coupling of 
the Pc to the LDL. Extensive studies have investigated serum proteins as drug carriers 
and merit acknowledging. 
6.3 Seru.m proteins 
Serum proteins are predominantly responsible for the transport of photosensitizers 
throughout the body. Serum albumin generally transports hydrophilic PS whereas more 
hydrophobie PS localize preferentially in lipoproteins, leading to enhanced intracellular 
accumulation of the dye via receptor mediated endocytosis (Table 6.1) (Rosenthal, 1991; 
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Reddi, 1997; Hamblin and Newman, 1994a). To further benefit from this, coupling of 
photosensitizers with albumin and low-density lipoproteins (LDL) prior to administration 
has been investigated as a means to deliver PS with higher target specificity. 
6.3.1 Albumin 
Initial studies involved the non-covalent binding of PS to bovine serum albumin 
(BSA) prior to intravenous administration (Larrocque et al., 1996). Using two in vivo 
tumor models, murine mammary carcinoma and human colon carcinoma, tumor 
regression was observed at ZnPc doses of0.5 and 2.0 µmol per kg respectively. 
Alternatively, covalent conjugates were prepared using BSA and vanous 
photosensitizers. These biomolecules can enter the cell either via passive diffusion or via 
receptor mediated endocytosis. Tumor-associated macrophages accumulate higher levels 
of photosensitizer as compared to neighboring tumor cells (a nine fold increase in the 
case of porphyrins) (Hamblin and Newman, 1994b). It has been estimated that in several 
cancers over 50% of the tumor mass is of the macrophage lineage. Macrophages express 
high numbers of the scavenger receptor which is able to bind a wide range of ligands, 
shuttling them to endosomes and lysosomal compartments. This receptor readily binds 
oxidized LDL and maleylated bovine serum albumin but not the corresponding native 
proteins (Krieger et al., 1993 ). Thus by covalently attaching photosensitizers to the BSA 
molecule, specific targeting of this receptor ensues. 
Brasseur et al. reported that maleylated-BSA was covalently coupled to AlPcS4 
via one or two sulfonamide hexanoic amide spacer chains. The photosensitizers used in 
the preparation of these bioconjugates is the same as that used in the covalent labeling of 
the adenoviral proteins (chapter 4) and the LDL molecules (chapter 3). The Pc-conjugate 
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was readily taken up by the scavenger receptors on J774 cells. Mal-BSA-Pc was more 
photocytotoxic against this receptor-bearing cell line compared to a negative control 
(Brasseur et al., 1999). Similarly, rnal-BSA coupled to chlorin e6 exhibited increased PS 
accumulation and phototoxicity when using J774 cells as compared to non-target 
OVCAR-5 cells (Hamblin et al., 2000a; 2000b). Oye uptake was decreased after 
incubating the rnal-BSA-Ce6 with the cells at 4°C, indicating an endocytotic route of 
entry. 
6.3.2 Lipoproteins 
The current study evaluates low density lipoproteins (LDL) as potential dye 
carriers. LDL are particles that are naturally produced by the liver. Their primary role is 
to transport cholesterol and other lipids to various cells throughout the body. They 
possess a receptor-binding motif, apolipoprotein B-1 OO, which binds with high affinity to 
a LDL cell surface receptor and is subsequently internalized. Cancer cells naturally 
express greater numbers of these receptors, rnaking LDL particles attractive vehicles for 
drug targeting (Gueddari et al., 1993). 
Early in vivo studies showed that very hydrophobie photosensitizers could only be 
administered following inclusion in lipid material (Reddi et al., 1990). Therefore ZnPc 
was enclosed in various liposomes. Several studies have investigated the interactions of 
LOL and liposomes containing ZnPc to determine whether the ZnPc becomes 
incorporated in the LDL (Valduga et al., 1999; Versluis et al., 1994; Rensen et al., 1994). 
Following in vitro incubation of the LDL and liposomes, the LDL particles acquired a net 
negative charge as seen using electrophoretic mobilities. This is indicative of ZnPc 
loading into the LOL. Consequently, intravenous injection of liposomal Pc showed that 
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LDL particles were indeed involved in Pc transport. Therefore, studies in which the 
ZnPc was non-covalently complexed with LDL prior to injection showed a two-fold 
greater tumor uptake of the Pc than when the Pc was enclosed in DPPC liposomes (Reddi 
et al., 1990). Accordingly, the use of the LDL receptor pathway as a tool for enhancing 
the selectivity of PS delivery to tumor cells has been extensively studied (Mazière et al., 
1991; lori et al., 1993). 
AlPc was non-covalently incorporated into oxidized LDL and the photodynamic 
efficiency evaluated. The oxidized LDL-Pc complex was taken up by the scavenger 
receptor after incubation with macrophages. Incubation of this Pc-LDL complex in 
serum revealed that it was quite stable, showing very little re-distribution amongst the 
other serum components (de Vries et al., 1999). In addition, LDL were non-covalently 
labeled with hematoporphyrin. Selectivity of tumor targeting was prominent. Electron 
microscopy demonstrated that the Hp-LDL conjugate induced direct tumor cell kill as 
opposed to the indirect effect seen when free Hp is administered. This suggested that 
targeting was through the LDL receptor pathway as the Hp-LDL seemed to be taken up 
by the cells via receptor-mediated endocytosis (Zhou et al., 1988). 
Chapter 3 outlines the study whereby AlPcS4 with a twelve carbon alkyl chain 
(C12) was non-covalently inserted into the phospholipid moiety of the LDL (Figure 3.1 ). 
ln vitro PDT studies on adenocarcinoma lung cancer cells (A549 cells), which have 
increased LDL receptor expression, using the AlPcS4C12 conjugate were very effective 
(Urizzi et al., 2001). The AlPcS4C12-LDL conjugate was twice as phototoxic as 
compared to the AlPcS4C 12, whereas, under similar experimental conditions, the parent 
molecule, AlPcS4, was inactive. The AlPcS4C 12-LDL bioconjugate was more 
67 
photoactive against the EMT-6 cell line. At doses as low as 0.2 µmol kg- 1, tumor 
regression was observed using the bioconjugate against the murine EMT-6 mode!. 
However as shown in chapter 2, the AlPcS4 derivatives substituted with long side chains 
exhibit similar tumor response and did not require coupling of the Pc with LDL prior to 
adrninistratio n. 
While non-covalent labeling of LDL particles showed promise, attempts to rnake 
covalent conjugates have been disappointing. LDL were covalently coupled with AlPcS4 
bearing two sulfonamide five carbon chains (A2) (Figure 3.1 ). Covalent coupling of the 
LDL protein moiety via the carboxylic acid groups of the monocaproic acid substituents 
reduced receptor recognition, thus decreasing cell/LDL-Pc interactions. Molar Pc:LDL 
ratios of approxirnately 70: l were maintained as this represented 90% labeling yield. 
Perhaps decreasing this ratio would enhance cell uptake of the biocoajugate leading to 
increased phototoxicity. This Pc conjugate was photo-inactive at the highest drug and 
light doses studied. An alternative explanation could be altered tra:fficking upon 
intemalization, without redistribution of the Pc to more photo-susceptible sites within the 
cell. Likewise, Hamblin and Newman conjugated LDL with hematoporphyrin via an 
amide bond which is similar to the present study (Hamblin and Newman, l 994c). 
Confocal microscopy showed that Hp-LDL localized in lysosomal compartments and that 
the LDL receptor was not solely responsible for uptake of this conjugate. Phagocytosis 
played a key role as well. 
Alternatively, other photosensitizers have been covalently attached to LDL via 
carbodiimide activation such as chlorin e6 (Schrnidt-Erfurth et al., 1997). LDL receptors 
on retinoblastoma cells were targeted. There was a 5-fold increase in chlorin e6 uptake 
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when using the LDL-Ce6 coajugate as compared to free Ce6. Similarly, the LDL-Ce6 
complex was very phototoxic. These results suggest that LDL could be used as dye 
carriers for intraocular tumors such as retinoblastomas thus avoiding invasive treatments. 
BPD non-covalently associated with LDL was likewise used to treat ocular 
conditions. It was observed that BPD-LDL accumulation was insignificant in LDL 
receptor negative fibroblasts or when the LDL was chemically modified. Furthermore, in 
vivo studies in Ml tumor bearing DBA/2J mice showed a pronounced enhancement of 
BPD-native LDL tumor accumulation over that of acetylated LDL associated BPD 
(Allison et al., 1994). These results indicate that the LDL receptor is responsible for the 
uptake of the BPD-LDL. Subsequently, BPD-LDL photodynamic therapy was tested on 
an experimental model of choroidal melanoma (Schmidt-Erfurth et al., 1994), 
experimental choroidal neovasculature (Miller et al., 1995) and Greene melanoma 
(Schmidt-Erfurth et al., 1996). Results were favorable in all three models indicating LDL 
usefulness as a sensitizer delivery vehicle. 
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Table 6.1 Summary of photosensitizer serum-based vehicles and bioconjugatès 
Vehicle Photosensitizer Target Reference 
Albumin (BSA) Hematoporphyrin Macrophages Hamblin and 
Newman 1994 
Albumin (BSA) ZnPc Murine mammary Larroque et al. 1996 
and human colon 
carcinoma 
Albumin (BSA), Chlorin e6 Tissue solder Khadem et al., 1999 
Fibrinogen, Gelatin 
Maleylated BSA Chlorin e6 Scavenger receptor Nagae et al. 1998 
Intimal hyperplasia 
Maleylated BSA AlPcS4A1 and A1 Scavengerreceptor Brasseur et al. 1999 
BSAand Chlorin e6 Scavengerreceptor Hamblin et al. 2000 
Maleylated BSA 
LDL ZnPc MS-2 fibrosarcoma Reddi et al 1990 
LDL TPPSn LDL receptor on de Smidt et al 1993 
human hepatocyte 
tumor 
LDL (human) BPD-MA Choroidal Schmidt-Erfurth et 
melanomas, al 1994 
choroidal Miller et al., 1995 
neovasculature 
LDL,HDL Hematoporphyrin LDL receptor on Hamblin and 
fibroblast Newman, 1994 
Scavenger receptor Hamblin and 
Newman, 1994 
LDL BPD-MA LOL receptor on Allison et al 1994 
rhabdomyosarcoma 
LDL (human) BPD-MA Greene melanoma Schmidt-Erfurth et 
al 1996 
LDL (human) Chlorin e6 Retinoblastoma Schmidt-Erfurth et 
al 1997 
LDL ( oxidized) AlPc Scavenger receptor Devries et al l 999 
LDL AlPcS4A2 and LOL receptor of Urizzi et al 2000 
AlPcS4(C12) lung 
adenocarcinoma 
Transferrin Hematoporphyrin Transferrin receptor Hamblin et al. 1994 
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6.4 Antibody conjugates 
A class of protein vehicles is the antibody vehicles. Photodynamic therapy using 
PS-Ab conjugates, termed photoimmunotherapy (PIT), has been developed over the past 
15 years (Hasan et al., 1997; Klyashachitsky et al., 1994). PIT has evolved in parallel 
with the use of monoclonal antibodies as pharmaceuticals. PIT is an ever-expanding field 
of study as mAb generation techniques improve thus generating different antibodies to be 
coupled with various photosensitizers. Targeting of photosensitizers using antibodies 
and/or fragments has been extensively investigated. Table 6.2 is a summary of various 
studies. 
6.4.1 Phthalocyanines 
Phthalocyanines have likewise been targeted to various cell lines via antibody 
carriers. AlPcS0 was encapsulated in liposomes that were then linked to antibodies for 
targeting purposes. It was clear from these early studies that the phototoxicity was 
directed by the mAb because free Pc or liposomal Pc were not phototoxic against the 
antigen-bearing cell lines under the same conditions (Morgan et al., 1989). Subsequently, 
this liposornal AlPcS0 formulation was used to target B-cells using an anti-B-cell Ab as 
well as T-lymphocytes using anti-CD3 antibody. This could be applicable for ex vivo 
bone marrow purging (Morgan et al., 1992). A similar method has also been used to 
target hurnan bladder carcinorna (Morgan et al., 1994). An AlPcS4A1 (A1 being a 5 
carbon spacer chain) has been used to label anti-carcinoembryonic antigen (CEA) 
monoclonal antibodies. This is the same Pc derivatives used to label proteins in the 
current study. The Pc-mAb conjugates had 5-16 moles of Pc per mol of antibody. The 
immunoreactivity of the bioconjugates was not altered due to the coupling with a 
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photosensitizer. ln nude mice, tumor to normal tissue ratios were similar for the Pc-mAb 
conjugates as compared to the free antibody. ln vitro, the bioconjugate was 
photocytotoxic against antigen positive cells. This, taken together with the in vivo tumor 
seeking capacity of the Pc-mAb, makes it a promising third generation photosensitizer 
(Carcenac et al., 1999). Conversely, an anti-CD3 antibody was covalently labeled with 
AlPcS4A1• Cell uptake of the bioconjugate was not impaired as measured by flow 
cytometry. However, the bioconjugate was not photoactive (Ménard, 1998). It was 
postulated that upon intemalization of the Pc-mAb, the photosensitizer was trapped in the 
endosome and following illumination, the singlet oxygen produced was quenched by the 
Pc-mAb microenvironment. 
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Table 6.2 Summary of photosensitizer-antibody conjugates 
Antibody Photosensitizer Target Reference 
Rabbit anti-Hu Hematoporphyrin Human perpherial blood Mew et al., 1985 
CAMAL-1 leukocytes 
Ll210 CAMAL antigen 
Irrelevant MoAb 
Anti-Leu/l Chlorin e6 T-leukemia cells Oseroff et al., 1986 
Mab 3G2/C6 Chlorin e6 Bladder carcinoma Hasan et al., 1989 
Mab 791T/36 Liposomal AlPcS Osteosarcoma, colorectal Morgan et al., 1989 
carcmoma 
Mab 309 Hematoporphyrin Gastrie cancer Xu et al., 1989 
Mab 3Hl 1 derivative 
Mab T48 BPD-MA Human chorionogonadotropic Jiang et al., 1990 
(HCG) hormone 
Rabbit IgG anti- Iodinated E. coli Devanathan et al., 
E.coli fluorescein 1990 
Mab0Cl25 Chlorin e6 Ovarian carcinoma Goff et al., 1991, 
1994, 1996 
Hamblin et al., 1996 
Mab HMFG-1 Hematoporphyrin Breast adenocarcinoma Prosser et al., 1991 
MabE7 Liposomal AlPcS Urinary bladder carcinoma Morgan et al., 1994 
Mab OC125 Chlorin e6 Human ovarian cancer Duska et al., 1997 
Mab0KT3 AlPcS4A1 Leukemic T lymphocytes (CD3+) Menard, 1998 
Mab U36 m-THPC Head and neck squamous cell Vrouenraets et al., 
carcmoma 1999 
Mab 35A7 AlPcS4A1 Carcinoembryonic antigen (CEA) Carcanac et al., 1999 
MabU36 TrisMPyP- Squamous cell carcinoma Vrouenraets et al., 
Mab425 <DC02H 2000 
Murine Mab Chlorin e6 Human colorectal cancer antigen Del Governatore et 
17.lA (EpCMA) al., 2000(a, b) 
Hamblin et al., 2000 
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6.5 Epidermal growth factor 
Epidermal growth factor (EGF) is a small protein that binds to a cell surface 
receptor. EGF is a potent mitogen found throughout the body and is classified as an 
angiogenesis stimulating factor. As seen with integrin receptor expression, the EGF 
receptor (EGF-R) is over expressed in a variety of tumor types, in particular ovarian 
cancers. 30% of ovarian cancers have increased EGF receptor numbers, making EGF a 
potential drug carrier (Moor et al., 2000). EGF has been coupled to various 
photosensitizers in the hopes of specifically targeting this receptor. The cytotoxic 
activities of an AlPc and a CoPc bound to EGF were determined against a human breast 
carcinoma cell line. The AlPc-EGF was seven times more photoactive as compared to 
the free AlPc. The CoPc-EGF conjugate was cytotoxic, requiring ascorbic acid for 
activation as opposed to light. In vivo studies using B 16 melanoma were subsequently 
carried out (Lutsenko et al., 1999). 
More elaborate conjugates have been prepared using EGF and Sn(IV)chlorin e6 
bound together via carriers such as dextran, polyvinyl alcohol and human serum albumin 
(HSA) (Gijsens and de Witte, 1998; Gijsens et al., 2000). The EGF-HSA-SnCe6 
conjugate had the best receptor affinity displaying high phototoxicity against a cell line 
over-expressing the EGF-R. The effect was receptor related as native EGF could 
compete for binding sites and decreased photoactivity. The HSA conjugate also 
produced more intracellular ROS upon irradiation as compared to the dextran conjugate. 
In a previous study, the EGF-Dex-SnCe6 conjugate bound specifically to the EGF 
receptor on a squamous cell carcinoma line whereas the EGF-PV A-SnCe6 conjugate 
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displayed limited binding. It was concluded that the photodynamic activity of these 
conjugates was dependent on the carrier used. 
6.6 Adenoviral Carriers 
Adenoviral pro teins were studied as protein carners for AlPcS4 ( chapter 4 ). 
Adenoviruses have natural tropism for a variety of tissue types. Adenoviruses enter ce Ils 
via receptor mediated endocytosis involving two separate receptors. The first one, 
designated as CAR (Coxsacchi and Adenovirus Receptor), is responsible for mediating 
attachment while the second receptor is responsible for internalization. This second 
receptor is a member of the integrin class of surface receptors. As previously stated, 
integrin receptor expression is frequently altered in cancer cells. Studies have shown that 
human lung cancer cell lines such as A549 (used in the current study) have increased 
expression of RGD binding integrins on the cell surface (Hirasawa et al., 1994). This 
would suggest that adeno-vectors could function as selective carriers to deliver 
photosensitizers specifically to lung cancer cells. 
Adenovirus type 2 capsid proteins were covalently labeled usmg an AlPcS4 
derivative via one or two caproic acid spacer chains (Figure 4.2). The specific 
adenovirus capsid proteins, the hexon, the penton base and the fiber were purified and 
conjugated with the Pc. The purification procedures were long and tedious resulting in 
only minimal amounts of purified proteins. Therefore, a mixture of adenovirus type 2 
soluble proteins was also covalently coupled with AIPcS4A2 • The bioconjugates were 
found to be only slightly photoactive in vitro when using the receptor positive cell line, 
A549 ceHs. ln vivo studies were more promising. The Ad2-soluble protein mixture 
labeled with the AIPcS4A2 derivative, at doses of 0.5 µmol kg- 1 and 400 J cm·2, resulted 
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in complete tumor regression using the EMT-6 model. This was a 20 fold decrease in Pc 
dose as compared to the parental AIPcS4 . Within the adenoviral protein mixture, the 
appropriate combination of viral proteins may be present invoking endosomal 
degradation to release the Pc. Endosomal entrapment of the photosensitizer has been 
proposed as an explanation for the decreased photocytotoxicity induced by the Pc 
conjugated with the purified penton base. This would prevent targeting of the PS to 
susceptible intracellular sites. 
Increased cell uptake of the bioconjugate over that of the free Pc was seen, as 
would be expected due to the presence of integrin surface receptors that can readily bind 
the RGD motif of the penton base. However, there was only marginal cell kill after 
irradiation in vitro. Several factors are required to release the contents of the endosome 
upon intemalization, in particular the adenoviral protease (Cotton and Weber, 1995). 
Therefore one could foresee using an attenuated adenovirus covalently labeled with a 
phthalocyanine as a delivery vehicle. The virus could be modified in such a way as to 
express one or more integrin binding ligands (RGD sequences) at the knob of the fi.ber 
protein. Upon binding via the RGD/integrin interaction, the virus-Pc would be 
internalized. The subsequent release from the endosome would be facilitated due to the 
use of an intact viral partie le. 
Sophisticated experiments were conducted using chlorin e6 as a photosensitizer, 
insulin as an intemalizable ligand and the SV 40 large T antigen as a nuclear localizing 
signal. These were all bound to BSA, a protein carrier. This conjugate was co-
administered with an attenuated adenovirus (Akhlynina et al., 1999). Insulin/receptor 
complexes are intemalized into endosomes and this is a limiting factor in the nuclear 
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transport of the conjugate as it limits the distribution of the sensitizer from locating in 
photosensitive sites. Adenoviruses aptly break open endosomes upon infection and 
therefore it was postulated that the bioconjugates would target the nucleus much more 
quickly and efficiently in the presence of adenoviruses. This indeed proved true. 
Rosenkranz and Sobolev have written comprehensive rev1ews on this subject 
(Rosenkranz et al., 2000; Sobolev et al., 2000). 
Adenoviruses have yet another potential role in photodynamic therapy, that of a 
gene therapy vector. A yeast vector system for manipulating the adenoviral genome has 
been developed and used to construct a virus expressing a mutant form of ALA-synthase 
(Gagnebin et al., 1999). This mutated enzyme Jacks the iron response element which 
regulates its translation and import to the mitochondria. This lead to the accumulation of 
endogenous photosensitizers in infected cells, conferring photosensitivity. Unlike 
conventional PDT this viral approach restricts photosensitivity by biological rather than 
purely physical or chemical means thus improving targeting. 
6. 7 Advances toward peptidic carriers 
Small peptides are readily prepared by automated solid phase peptide synthesis. 
The several possible combinations of natural and non-natural amino acid sequences make 
this a versatile class of molecules. In addition peptidic vectors are desirable as they 
invoke minimal humoral and sytemic immune responses. The RGD motif binds with 
high affinity to several of the integrin class of cell surface receptors. As discussed in 
chapter 5, RGD peptides have several therapeutic applications. One such application was 
as a stimulator of apoptosis, in particular of endothelial cells of angiogenic vessels 
(Brooks et al., 1994). A second potential use is as a carrier for chemotherapeutic agents 
77 
such as doxorubicin (Arap et al., 1998). In the hopes of developing either a peptidic 
carrier system for phthalocyanines or an adjunct therapy to PDT, chapter 5 details a study 
of an RGD containing peptide used in conjunction with AlPcs2adj PDT. It was found that 
a soluble RGD peptide attenuated PDT induced apoptosis. Generally, a soluble RGD 
peptide, when in contact with adherent cells disrupts the extracellular matrix thus 
blocking integrin signaling to the ECM and stimulates apoptosis. Buckley proposed an 
alternative method, that soluble RGD causes apoptosis via directly binding to and 
activating procaspase 3 (Buckley et al., 1999). At higher concentrations (10 mM) of the 
RGD peptide, we observed apoptosis with both a receptor positive and a receptor 
negative cell line therefore suggesting no involvement of the integrin receptor. At 
slightly inferior concentrations, there was a protection against PDT induce apoptosis in 
both cell lines with a much more pronounced protection in the receptor positive A549 
cells. Not to completely rule out integrin receptor involvement, Whitlock and associates 
found that integrin signaling could either enhance or inhibit apoptosis of 
neutrophils depending on the proapoptotic stimuli (Whitlock et al., 2000). Activation of 
this class of integrins accelerated apoptosis induced by UV irradiation, Fas ligation and 
TNFa. However, integrin clustering without activation, resulted in inhibition of 
apoptosis. 
In the current study, quenching of the reactive oxygen species by the peptide was 
ruled out as several different experimental parameters were changed to physically remove 
the peptide prior to PDT. The protective effect was still apparent and significant in the 
A549 cells whereas in the receptor negative cell line, EMT-6, the protection against 
apoptosis was almost abrogated. It was proposed that the RGD peptide, when rinsed, was 
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readily released from the EMT-6 cells, thus diminishing the protective effects whereas in 
the A549 cells, the peptide release was less. Studies using a radiolabeled peptide could 
prove useful in this capacity to determine peptide movement across the different cell 
membranes. 
The A549 cells were previously shown in chapter 4 to bind with high affinity the 
radiolabeled RGD peptide whereas no significant binding was apparent in the EMT-6 
cells. It is interesting that RGD has the most effect on A549 apoptosis. It could be 
possible that two different mechanisms are involved in the protective effect depending on 
the cell line. A549 cells, when incubated ovemight with RGD prior to Pc-PDT, had 
enhanced cell survival whereas the EMT-6 had none. Perhaps, a receptor mediated, 
albeit a low affinity binding receptor, plays arole in the A549 protection whereas, simple 
diffusion of the peptide across the EMT-6 membrane may account for enhanced EMT-6 
cell survival under certain circumstances. In the former, perhaps there is increased anti-
apoptotic protein expression required to decrease cell death, whereas in the latter, perhaps 
the RGD is able to get into the cell and physically disrupt the apoptotic cascade. 
Studies involving an irnmobilized RGD peptide could help elucidate whether cell 
penetration is required to abrogate apoptosis. In addition, it was postulated that increased 
expression of anti-oxidants such as superoxide dismutase, glutathione peroxidase and 
catalase may be a result of RGD stimulated integrin signaling (Qin et al., 2001). 
Clustering and activation of integrin receptors promotes de novo protein synthesis which 
was an absolute requirement to promote the survival effect of the extracellular matrix 
(Bozzo et al., 1997). Hence, growing cells on RGD coated plates, prior to PDT, may help 
to determine whether integrin signaling is involved in cell survival under these 
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circumstances. Analysis of protein levels could prove invaluable m elucidating the 
signais involved in RGD protection from PDT induce apoptosis. 
6.8 Conclusion 
Since its fortuitous beginning a century ago, photodynamic therapy has grown 
exponentially into a useful therapy for a number of conditions. The clinical acceptance 
of Photofrin®, methyiene blue, Visudyne™ and the prodrug ALA clearly shows the 
extreme promise of PDT as a treatment for both rnaiignant and non-malignant conditions 
for which there are few other useful therapies. There are a number of second generation 
photosensitizers in the pipeline with superior photophysical and biological properties. 
The choice of vehicles and carriers has dramatic effects on the properties of these 
photosensitizers. Clearly the investigation and development of new vehicles and 3rd 
generation photosensitizers could allow PDT to reach its full potential. There remains a 
long list of potential vehicles and carriers for photosensitizers including growth factors, 
hormones, steroid analogs, signaling molecules, peptides, antibody fragments, viral 
components, oligonucleotides and other tumor and tissue specific compounds. 
The current study confirms that phthalocyanines are potent photosensitizers that 
are readily substituted, yielding better uptake and photodynamically active agents. 
Monosubstitution of AlPcS4 with carbon chains of varying lengths increases the efficacy 
of this photosensitizer both in vitro and in vivo. L-Tryptophan oxidation fo llowing 
irradiation surpassed that of the parental AlPcS4 molecule when the lipophilic sensitizers 
were monomerized in l % CRM. Cell adsorption as well as photocytotoxicity using the 
A549 cell line varied directly with the degree of hydrophobicity: Cl6 > Cl2 > C8 > C4. 
A549 cells took up 7 times more AlPcS4(C16) as compared to AlPcS4(C4) after a 48 hour 
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incubation. Human LDL at 4 µg/mL decreased cell uptake of the Pc derivatives but had 
little or no affect on the cytotoxicity of the sensitizer presumably due to better subcellular 
localization. These lipophilic phthalocyanines were potent sensitizers in vivo using the 
EMT-6 tumor model. Complete tumor regression was obtained at doses as low as 0.2 
µmol kg- 1 using both the Cl2 and the Cl6 derivatives whereas AlPcS4 was inactive at 
doses 25 times greater. 
Protein carriers such as lipoproteins enhance targeting of the sensitizer to cancer 
cells which can overexpress the LDL receptor (Gueddari et al., 1993). Attachment of 
AlPcS4 via covalent coupling to the apolipoprotein through a caproic acid spacer chain or 
via non-covalent adsorption of AlPcS4(Cl2) in the phospholipid part of the LDL was 
used to further determine the utility of LDL as a sensitizer transporter. The AlPcS4A2-
LDL bioconjugate was only slightly phototoxic in vitro with LD90 values of 27 and 33 J 
cm·2 against the EMT-6 and A549 cell lines, respectively. LD90 values of 2 and 4 J cm·2 
were measured for the non-covalently labeled AlPcS4(Cl2)-LDL conjugate using 
identical experimental conditions. Clearly, LDL-association with lipophilic 
phthalocyanines via adsorption into its phospholipid bilayer augments the in vitro 
phototoxicity of the Pc. However, in vivo, the EMT-6 tumor response of the free 
AlPcS4(C 12) is similar to that of the LDL-associated dye, most likely due to the known 
redistribution of amphiphilic photosensitizers to serum lipoproteins upon injection. 
Adenovirus proteins were studied as potential Pc carriers. AlPcS4 was covalently 
coupled to various adenovirus type 2 capsid proteins, including the hexon, penton base 
and fiber, via one or two caproic acid spacer chains in 7:1 to 66:1 molar ratios. 
Adenoviruses gain access to cells via receptor-mediated endocytosis. Adenoviruses 
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attach to cells via the fiber capsid protein/receptor interaction while cell intemalization 
involves binding of the virus to av integrins, a process mediated by RGD sequences 
found in the penton base of the adenoviral capsid. Cell adsorption studies were carried 
out on the integrin receptor positive A549 cell line. Ali Pc bioconjugates exhibited 
significantly improved cell uptake as compared to free Pc derivatives. In the meanwhile, 
the photocytotoxicity of the bioconjugates was determined against integrin receptor 
positive A549 and HEp2 and receptor negative EMT-6 cells. The Pc bioconjugates 
showed improved activity compared to the parent compounds in the receptor positive cell 
lines. Pcs labeled with the RGD-containing penton base were most phototoxic requiring 
roughly half the light dose to induce 50% cell kill as compared to the unlabeled 
compound. Complete tumor regression of EMT-6 tumors implanted on Balb-c mice was 
obtained using a mixture of adenovirus type 2 soluble proteins convalently labeled with 
AlPcS4A2 at a dose of 0.5 µmol kg- 1 and 400 J cm-2. Unlabeled AlPcS4A2 requires l 
µmol kg- 1 at the same light dose. This suggests that the high affinity RGD/receptor 
complex is able to target phthalocyanines for PDT. 
The effect of an RGD containing peptide on the photodynamic action of AlPcS2adj 
was studied in vitro using both a receptor negative and a receptor positive cell line, EMT-
6 and A549 cells, respectively. At elevated RGD concentrations, 2::10 mM, RGD induced 
apoptosis. However at lower concentrations, the RGD abrogated the apoptotic effect of 
PDT in both cell lines, the effect being more pronounced in the A549 cells. At an RGD 
concentration of 50 µM, there was over 75 % A549 cell survival following AlPcS2adj 
PDT. Only 30 % survival was observed when no RGD peptide was administered. The 
protection is seemingly independent of the integrin receptor because it is observed in the 
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receptor negative cells and the concentrations required are higher than those needed to 
saturate the receptor. 
Further studies are warranted to elucidate the signaling properties of the RGD 
peptide. Only when we fully understand its role in apoptosis can we strategize to 
improve current PDT protocols. However, this work has clearly helped phthalocyanines 
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